Q1 2025 EPS Estimates for Vertex Pharmaceuticals Incorporated Increased by Analyst (NASDAQ:VRTX)

Posted by Defense World Staff on Apr 8th, 2024

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) – Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Vertex Pharmaceuticals in a report released on Wednesday, April 3rd. Zacks Research analyst R. Department now forecasts that the pharmaceutical company will earn $3.52 per share for the quarter, up from their previous estimate of $3.48. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $14.95 per share. Zacks Research also issued estimates for Vertex Pharmaceuticals’ Q2 2025 earnings at $3.73 EPS, Q4 2025 earnings at $3.82 EPS, FY2025 earnings at $14.81 EPS and Q1 2026 earnings at $3.75 EPS.

Other equities analysts have also recently issued research reports about the company. Evercore ISI cut Vertex Pharmaceuticals from an “outperform” rating to an “in-line” rating and boosted their price objective for the stock from $436.00 to $438.00 in a research report on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $440.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 20th. Maxim Group cut Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group cut Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and boosted their price objective for the stock from $332.00 to $379.00 in a research report on Wednesday, January 24th. Finally, Sanford C. Bernstein cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Friday, February 2nd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $420.48.

View Our Latest Stock Report on VRTX

Vertex Pharmaceuticals Stock Performance

VRTX opened at $406.67 on Monday. The company has a market cap of $105.05 billion, a PE ratio of 29.28, a price-to-earnings-growth ratio of 2.21 and a beta of 0.35. The stock has a 50-day moving average of $419.77 and a 200-day moving average of $394.40. Vertex Pharmaceuticals has a 52-week low of $316.43 and a 52-week high of $448.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.85 by $0.35. The company had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same quarter in the prior year, the company posted $3.33 EPS.

Institutional Trading of Vertex Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC lifted its holdings in shares of Vertex Pharmaceuticals by 8.1% in the first quarter. GAMMA Investing LLC now owns 2,168 shares of the pharmaceutical company’s stock valued at $906,000 after purchasing an additional 163 shares in the last quarter. Capital Market Strategies LLC increased its position in shares of Vertex Pharmaceuticals by 21.8% in the first quarter. Capital Market Strategies LLC now owns 1,157 shares of the pharmaceutical company’s stock valued at $484,000 after acquiring an additional 207 shares during the last quarter. CWM LLC increased its position in shares of Vertex Pharmaceuticals by 8.5% in the first quarter. CWM LLC now owns 6,040 shares of the pharmaceutical company’s stock valued at $2,525,000 after acquiring an additional 475 shares during the last quarter. Orrstown Financial Services Inc. acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $216,000. Finally, Strategic Advocates LLC acquired a new stake in shares of Vertex Pharmaceuticals in the first quarter valued at about $2,323,000. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 354 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $425.70, for a total transaction of $150,697.80. Following the transaction, the executive vice president now directly owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the transaction, the chairman now owns 27,644 shares in the company, valued at $11,596,934.44. The disclosure for this sale can be found here. Insiders sold a total of 12,381 shares of company stock valued at $5,203,249 over the last three months. Company insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.